Company Overview
Travere Therapeutics, Inc. operates as a biopharmaceutical entity focused on identifying, developing, and delivering therapies for individuals living with rare kidney and metabolic diseases within the United States market. The company functions within the broader healthcare sector, specifically categorized under the biotechnology industry, which implies a reliance on research and development to create novel treatments for specialized patient populations. As of the latest data, the organization supports a workforce of 497 employees and maintains a total market capitalization of $2.49 billion. With annual revenue reaching $490.73 million, these figures indicate that Travere Therapeutics has achieved significant scale, positioning it as a substantial player capable of funding extensive clinical programs and commercialization efforts for its pipeline products like FILSPARI.
Financial Health
The company reported revenue of $490.73 million for the trailing twelve months, while the net income stood at -$50.26 million, resulting in an EBITDA of -$2.08 million. The substantial gap between the positive revenue figure and the negative net income reveals a heavy cost structure driven by ongoing research, development, and administrative expenses typical of early-stage to mid-stage biotechnology companies. Free cash flow for the period was -$38.30 million, indicating that the company is currently burning cash to fund operations and growth initiatives rather than generating surplus liquidity for distribution or debt reduction. Gross margin is reported at 55.9%, which suggests that the cost of goods sold relative to revenue is controlled, yet the operating margin of -25.0% and profit margin of -5.2% demonstrate that overhead costs significantly erode profitability before tax. Return on Equity is -57.8% and Return on Assets is -6.5%, metrics that collectively indicate the company is currently allocating capital to generate losses rather than returns, a common characteristic for firms prioritizing asset expansion over immediate profit generation. The balance sheet shows cash holdings of $322.80 million against total debt of $328.73 million, resulting in a debt-to-equity ratio of 286.28, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the high leverage, the current ratio of 2.74 indicates that the company holds more than two and a half times the current assets relative to current liabilities, suggesting adequate short-term liquidity to meet obligations as they come due.
Valuation Assessment
Travere Therapeutics does not have a trailing P/E ratio available due to lack of net income, but the forward P/E is listed at 6.33, which implies that the market is pricing the stock based on future earnings expectations rather than historical profitability. The price-to-book ratio stands at 21.36, indicating that the market values the company's equity at over 21 times its book value, reflecting a significant premium assigned to the intellectual property and future growth potential of the biotechnology firm. Alternative valuation metrics such as the price-to-sales ratio of 5.07 and an EV/EBITDA of -1192.55 suggest that investors are willing to pay a high multiple of sales despite negative earnings, a standard valuation approach for unprofitable growth companies where revenue expansion is the primary driver of value. The stock has traded between a 52-week low of $12.91 and a 52-week high of $42.13, and based on the forward P/E of 6.33, the current valuation implies an expectation of future earnings normalization or significant growth to justify the price relative to the historical trading range. The beta value of 0.88 suggests that the stock's price volatility is slightly lower than the broader market, meaning it may be less sensitive to general market fluctuations compared to a stock with a beta greater than one.
Growth & Income
Revenue growth for the trailing twelve months was 73.4% year-over-year, while earnings growth is not applicable due to the company reporting a net loss, which implies that the company is prioritizing revenue expansion over immediate profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available cash flow and generated capital back into research, development, and commercialization rather than distributing income to shareholders. The absence of dividend payments is consistent with the company's financial profile, where free cash flow is negative and management focuses on scaling the business to capture market share in rare disease therapies. The overall growth and income profile is defined by rapid revenue acceleration coupled with significant cash consumption, creating a high-risk, high-reward scenario typical of biotechnology firms in the growth phase that have not yet reached sustainable profitability.